Stock Upgrades Today Show Top Picks

 TopRated
 
  TopRated
 
Follow  Message
 
 
 
TopRatedStocks uncovering top-rated companies. Providing quick insights and recommendations, they help investors discover high-potential stocks based on robust metrics.
 

•  12 Dec 2025
 

•   AAL  
   
  -0.66%
•   AMZN  
   
  -0.44%
•   ANAB  
   
  -1.10%
•   ANF  
   
  -1.49%
•   APP  
   
  -2.25%

$AAL UBS leans in on American Airlines with a Buy call tied to expanding profit leverage and a cleaner capacity path. The firm argues AAL yield recovery and disciplined cost structure position the carrier for stronger operating margins in upcoming quarters despite macro turbulence.

$AMZN TD Cowen reiterates Buy on Amazon as upside drivers concentrate around AWS reacceleration, durable gross-margin expansion and higher retail efficiency. The 28.55 percent implied upside underscores confidence in Amazon multiyear reinvestment cycle.

$ANAB Stifel maintains Buy on AnaptysBio, pointing to a pipeline positioned for meaningful catalysts in inflammation and immunology. With a 34.27 percent modeled upside, the firm highlights valuation dislocation relative to clinical optionality.

$ANF Goldman Sachs initiates Abercrombie & Fitch at Buy, citing a structurally improved merchandising engine, stronger brand heat and tightening inventory discipline. Upside is modest near-term but reflects a view that ANF operating cadence is sustainably upgraded.

$APP Benchmark and Jefferies both maintain Buy on AppLovin, pointing to durable platform monetization and improved advertiser engagement. With roughly 2.5 percent modeled upside, the call reflects incremental but credible momentum in the software and gaming ad stack.

$ARGX Stifel reiterates Buy on argenx, highlighting long-run growth anchored in Vyvgart expansion and new autoimmune opportunities. With 10 percent modeled upside, the firm views pullbacks as accumulation opportunities.

$ARWR RBC Capital maintains Outperform on Arrowhead despite flagging a 16.35 percent downside risk in valuation models. The call reflects confidence in Arrowhead platform but acknowledges near-term volatility linked to program timing.

$ASND Stifel maintains Buy on Ascendis Pharma, pointing to robust endocrinology pipeline execution and improved commercial traction. The 26.82 percent upside suggests meaningful room for rerating.

$ASTH Needham initiates Astrana Health at Buy with a 28 price target, supported by a scaled value-based care model and sustained membership growth. Loop Capital also initiates, reinforcing a constructive multi-year outlook.

$ATEC Freedom Capital initiates Alphatec at Buy, noting competitive differentiation in spine hardware and accelerating adoption. With 22.47 percent upside, analysts see a favorable innovation cycle ahead.

$ATLC Citizens maintains Market Outperform on Atlanticus, highlighting strong credit performance and disciplined loan growth. Forecasts suggest double-digit upside as the firm leans into earnings durability.

$BBOT Wedbush reiterates Outperform on BridgeBio Oncology Therapeutics, calling out a high-conviction clinical pipeline. The 90.51 percent modeled upside reflects asymmetric reward potential.

$BFLY Craig-Hallum maintains Buy on Butterfly Network, citing platform enhancements like Compass AI. Analysts view BFLY as a long-duration bet on handheld imaging democratization.

$BTE Baytex receives a rating shift from Raymond James to Outperform, with analysts citing improved production visibility. The upgrade reflects growing confidence in Baytex capital efficiency.

$CHWY Goldman Sachs maintains Buy on Chewy, pointing to resilient pet-spend trends and improving customer retention. The 34.19 percent upside outlook suggests the market undervalues margin expansion.

$CHYM B. Riley initiates Chime Financial at Buy, citing a differentiated digital-banking model with meaningful monetization runway. Upside near 16 percent anchors the call.

$CMP Deutsche Bank maintains Buy on Compass Minerals, viewing pricing discipline and specialty minerals demand as catalysts. The 15.12 percent implied upside remains constructive.

$CNP KeyBanc upgrades CenterPoint Energy to Overweight, citing clearer regulatory visibility and an improving rate-base trajectory.

$COST Analysts at BofA and Telsey reaffirm strong Buy and Outperform views, noting recurring loyalty strength, stable traffic and upside leverage to membership pricing.

$CVNA Jefferies maintains Buy on Carvana, retaining conviction in the retailer margin rebuild even as models indicate modest downside volatility.

$CVX BofA maintains Buy on Chevron, highlighting capital discipline and strong upstream cash-flow durability.

$DLO Truist upgrades DLocal to Buy, flagging attractive valuation entry points and improved execution in high-growth payment corridors.

$DTE Jefferies upgrades DTE Energy to Buy, expecting a favorable regulatory cycle and steady infrastructure investment.

$FDX Jefferies maintains Buy on FedEx as network optimization continues to support margin recovery despite softer parcel dynamics.

$FLUT Bernstein and Citizens split between Market Perform and Market Outperform, but both note Flutter strong digital share and improving U.S. margin profile.

$FULC Truist maintains Buy on Fulcrum Therapeutics, anchored in emerging clinical validation and a capital-efficient development strategy.

$GCTS HC Wainwright initiates Buy on GCT Semiconductor, projecting substantial upside tied to accelerating 5G design-wins.

$GIS Stifel maintains Buy on General Mills, highlighting pricing resilience and improved cost management.

$GL TD Cowen maintains Buy on Globe Life, viewing the insurer underwriting strength and consistent cash-flow profile as core drivers.

$GPCR Jefferies maintains Buy on Structure Therapeutics, emphasizing differentiated small-molecule innovation in cardiometabolic care.

$GTE Roth/MKM initiates Gran Tierra at Buy, citing drilling success and improving reserve expectations.

$IBRX D. Boral Capital maintains Buy on ImmunityBio with a high-conviction view on late-stage immunotherapy assets and significant modeled upside.

$IHG Jefferies upgrades InterContinental Hotels Group to Buy, supported by global RevPAR strength and expanding loyalty monetization.

$INSM TD Cowen maintains Buy on Insmed, citing advancing respiratory programs and durable revenue visibility.

$IONQ Mizuho initiates IonQ at Outperform, calling out accelerating quantum-compute commercialization.

$JEF Oppenheimer maintains Outperform on Jefferies, pointing to stronger advisory pipelines and capital-markets normalization.

$JNJ RBC Capital maintains Outperform on Johnson & Johnson, seeing stable pharma contribution even with modest model downside.

$KYMR Mizuho maintains Outperform on Kymera as protein-degrader momentum continues despite near-term valuation softness.

$LRCX Bernstein reaffirms Buy on Lam Research, emphasizing wafer-fab-equipment recovery and strong positioning across leading-edge nodes.

$NBIX Stifel maintains Buy on Neurocrine, citing durable revenue drivers and deepened neuroscience optionality.

$NDSN DA Davidson maintains Buy on Nordson, anchored in steady industrial demand and disciplined capital allocation.

$NFLX Jefferies maintains Buy on Netflix with 46.80 percent upside, highlighting strong ad-tier economics and accelerating subscriber momentum.

$PAC BofA upgrades Grupo Aeroportuario del Pacífico to Buy, noting normalized travel trends and improved yield dynamics.

$ORCL Stifel cuts Oracle target but maintains Buy, reiterating confidence in cloud transition and backlog expansion.

$PLAB Craig-Hallum and DA Davidson both maintain Buy on Photronics, citing long-term exposure to semiconductor photomask demand.

$PLAY Investors debate whether Dave & Buster remodel blueprint can accelerate traffic and monetization. Execution remains the swing factor.

$PLUG Craig-Hallum reiterates Buy on Plug Power, seeing long-term hydrogen optionality despite near-term balance-sheet scrutiny.

$QBTS Mizuho initiates Outperform on D-Wave Quantum with strong conviction in enterprise quantum adoption.

$RIO Argus maintains Buy on Rio Tinto, pointing to diversified commodity exposure and disciplined shareholder returns.

$RPRX TD Cowen maintains Buy on Royalty Pharma, citing durable cash flows from a diversified royalty portfolio.

$SATS A Wall Street analyst upgrade supports EchoStar recent momentum as investors reassess asset value and satellite-network potential.

$SNPS Rosenblatt maintains Buy on Synopsys while BofA upgrades the stock, citing continued leadership in EDA and AI-accelerated design technology.

$SOUN Cantor Fitzgerald upgrades SoundHound to Overweight, spotlighting accelerating AI-driven voice-processing demand.

$TMO Citigroup upgrades Thermo Fisher to Buy, forecasting renewed instrument demand and stable bioproduction trends.

$TOL KBW maintains Market Perform on Toll Brothers, with upside tied to affluent-buyer resilience and tight supply.

$TSLA Tesla Q4 discount strategy aims to pull forward Model Y demand and stabilize inventory turnover.

$TTI CJS Securities initiates Outperform on TETRA Technologies, highlighting specialty-chemicals leverage and margin expansion.

$TUYA CICC and Morgan Stanley reaffirm Buy on Tuya, noting strong IoT ecosystem traction and improving monetization.

$UEC Roth Capital reiterates Buy on Uranium Energy, projecting solid upside tied to uranium cycle strength.

$V BofA upgrades Visa to Buy, citing resilient payment flows and expanding cross-border volumes.

$VG BofA maintains Buy on Venture Global with triple-digit modeled upside driven by LNG capacity scaling.

$VZ Verizon’s Wi-Fi 6E upgrade enhances stadium network performance, reinforcing its enterprise-network leadership narrative.

$WRBY BTIG maintains Buy on Warby Parker, expecting omnichannel scale benefits despite near-term model pressure.

$XOMA HC Wainwright maintains Buy on XOMA while Leerink maintains Outperform, both pointing to significant royalty-based upside optionality.

View All Headlines